live esmo incyt fight cholangiocarcinoma win
reiter market outperform rate incyt corpor
increas price target base discount earn
per share revenu multipl analysi last friday report posit
updat result phase trial pemigatinib second-lin
cholangiocarcinoma cca european societi medic oncolog
esmo congress importantli patient enrol pleas
see respons rate larg maintain compar previou
updat ruxolitinib pois gener sale
pemigatinib nda file expans ruxolitinib multi-billion
dollar market dermatolog cash posit believ incyt
share repres limit downsid bear case scenario signific
potenti upsid bull case scenario
posit result maintain second-lin cca updat result
trial demonstr continu safeti efficaci
pemigatinib second-lin greater mutant cca trial met
primari endpoint orr patient treat cohort
also met secondari endpoint median progression-fre surviv
month versu month typic seen line therapi
base discuss fda includ breakthrough design
plan submit nda pemigatinib second-lin treatment
biomarker-defin subset cca
signific opportun cholangio beyond believ
pemigatinib approv second-lin cca could act wedg
space potenti open door futur approv frontlin cca
second-lin bladder cancer frontlin bladder cancer fgfr tumor agnost
indic estim could realiz peak risk-adjust revenu
figur eu cca bladder cancer
revenu cca built price target increas
probabl success indic believ franchis could
provid signific upsid potenti investor
inhibitor bar major differ efficaci safeti first drug
achiev approv indic like maintain market share given
similar mechan action prevent cycl drug
class therefor believ race front-lin set
meaning frontlin cca bladder cancer trial alreadi
initi
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
figur market model summari pemigatinib cholangiocarcinoma
bladder cancer
fgfr-target drug current develop pemigatinib demonstr
highest select modest inhibit suggest might
potent competitor fewer off-target effect figur whether
translat clinic provid competit advantag yet seen respect
second-lin cca howev pemigatinib lead term develop believ like
approv strength data present esmo import
treatment one fgfr-target therapi like preclud treatment anoth given similar
mechan action isnt say room multipl fgfr inhibitor given
indic rather first market might gain widest accept bar signific
differenti factor term efficaci safeti
pemigatinib fgfr inhibitor cholangiobladdertot address patient popul annual wac address market opportun address patient popul annual wac address market opportun market opportun us cholangio bladder market opportunitiesyear market penetr achiev market penetr success revenu market penetr achiev market penetr success revenu revenu risk-adjust revenu corpor
advanc competitor cca bridgebio nc drug infigratinib current
phase trial front-lin cholangiocarcinoma trail infigratinib basilea bpmuf nc drug
derazantinib licens arqul arql nc phase trial
figur select clinic fgfr agent
trial open-label single-arm studi design assess efficaci safeti
pemigatinib patient advanced/metastat surgic unresect cca studi design
enrol patient three cohort cohort includ patient fusions/rearrang
target enrol cohort includ patient fgf/fgfr mutat target
enrol cohort includ patient fgf/fgfr mutat target enrol
figur patient provid intermitt two week one week daili dose
pemigatinib mg primari endpoint studi orr confirm independ central
review cohort secondari endpoint orr cohort cohort combin
cohort dcr mpf mo safeti enrol complet patient
cohort cohort cohort patient still follow final result
primari endpoint orr obtain
patient screen fgfr statu determin elig treatment
figur rate lower fusion/rearrang rate quot
literatur manag note screen factor play screen patient
cca intrahepat manag confid rate cite literatur
notabl patient enrol cohort four withdrew studi due advers
event indic rel toler treatment pemigatinib
figur breakdown patient enrol
respect patient demograph figur patient cohort tend younger
cohort notabl median age cohort year younger
median age intrahepat cca occur gener popul year blechacz
potenti slightli skew result posit direct given younger patient
like toler treatment said median age patient treat infigratinib
esmo present even younger year regardless effect age differ
like minor observ
expect mutat major patient cohort intrahepat cca
figur patient treat cohort prior treatment one prior
treatment two greater equal three surpris given
treatment option avail cca patient patient cohort also tend rel
healthi ecog statu ecog statu
compar patient characterist releas infigratinib trial wherein
less equal one line prior treatment greater equal two line
prior treatment ecog ecog trend toward includ healthier
patient fewer line prior treatment surpris indic trial target
patient highest likelihood toler consequ respond treatment
result present esmo includ final orr met studi primari
endpoint compar orr report esmo figur given
twice mani patient seen data cutoff march compar last juli
encourag opinion high probabl support approv
upcom nda file pemigatinib second-lin cholangiocarcinoma patient
mutat similarli dcr maintain esmo esmo
addit mo increas month month could increas patient
continu follow acknowledg signific amount censor patient
median follow-up month one caveat random control
studi mo said treatment result said repres potenti
surviv benefit interest see flesh phase trial
figur updat result esmo compar esmo
piec data first blush seem neg decreas mpf month
month examin surviv curv howev reveal median matur data came
step account drop figur say
appear drastic differ patient look earlier compar entir data set
notabl even patient progress pemigatinib saw appreci decreas target lesion
size treatment pemigatinib figur
figur chang baselin lesion cohort
return previou comment made note trend toward younger healthier
patient trial breakdown orr patient characterist provid figur
unsurprisingli patient saw fewer line treatment demonstr higher orr
patient one prior line two ecog patient
also like respond orr ecog orr
surprisingli younger patient exhibit lower orr older patient mani
fewer older patient wider rang respons howev difficult read anyth meaning
fact
figur breakdown orr patient characterist
inter-studi comparison alway taken grain salt import tri
elucid differ efficaci safeti competit drug develop end
recent data two advanc fgfr inhibitor develop cca behind
pemigatinib includ figur mention earlier patient characterist trial
infigratinib pemigatinib similar lend credenc comparison orr infigratinib
derazantinib significantli lower pemigatinib respect
might turn larg gap data matur howev keep mind earlier
data cut prior esmo june data cutoff cohort orr
evalu patient term dcr drug line pemigatinib
infigratinib derazantinib mpf data avail derazantinib month
achiev infigratinib close match month pemigatinib total difficult choos
clear winner data matur infigratinib derazantinib neither least appear
show significantli better efficaci impress result present pemigatinib
figur data releas fgfr inhibitor cholangiocarcinoma
pemigatinib treatment gener well toler hyperphosphatemia common
patient
hyperphosphatemia effect manag low-phosph diet phosphat binder
diuret three patient experienc hyperphosphatemia requir dose reduct
interrupt hypophosphatemia report patient grade
postul relat overtreat hyperphosphatemia discontinu dose reduct
requir hypophosphatemia none event deem clinic signific
small number patient experienc seriou retin detach infigratinib show similar
level hyperphosphatemia patient hypophosphatemia patient
derazantinibal patientson fewer prior treatmentstwo prior treatmentsevalu month -- -esmo press releas incyt corpor
valu biotechnolog compani base blend discount earn per share
revenu multipl analysi first evalu univers profit biotechnolog compani
deriv revenu multipl rang ep multipl rang base compani trade
bear bull market end ascertain rang revenu multipl
earn per share multipl appli price-to-earnings multipl probability-adjust
earn per share approxim discount period obtain
fair valu per share appli revenu multipl probability-adjust
revenu discount period obtain per share fair valu
averag result two method ad current cash per share
million share deriv price target round
figur blend discount earn per share revenu multipl analysi
revenu estim combin increas sale exist commerci
product ruxolitinib mf pv sr-agvhd ponatinib cml baricitinib ra
potenti sale product believ high likelihood approv pemigatinib
cholangiocarcinoma ruxolitinib sr-cgvhd itacitinib sn-agvhd sn-cgvhd
base scenario includ potenti revenu rux cream sale mild
moder ad vitiligo pemigatinib sale bladder cancer
bull scenario adjust probabl success program base
confid data seen far includ risk-adjust revenu key pipelin product
valuat figur
result fair valu bear scenario remov risk-adjust revenu
itacitinib assum lower-than expect long-term jakafi sale base scenario fair
valu
bullbasebearrux cream ad cream ad cream vitiligo cream vitiligo sr-cgvhd sr-agvhd sr-cgvhd cholangio uretheli cancer cholangio uretheli cancer sn-agvhd sn-cgvhd sn-agvhd sn-cgvhd revenu mm dilut non-gaap ep success figur project incom statement annual
figur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad pemigatinib cholangio uc total product revenu product royalti contract revenue- mileston total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss interest interest incom expens non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor figur project incom statement quarterli
figur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad -- -- -- -- pemigatinib cholangio uc -- -- -- total product revenu product royalti contract revenue- mileston revenue- total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss interest interest incom expens net- non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor incyt corpor
wilmington delaware-bas incyt corpor drug discoveri develop compani grow pipelin novel small-molecul
drug treat variou inflammatori disord cancer
risk invest thesi valuat includ clinic develop competit regulatori sector
clinic develop risk drug develop riski capital-intens endeavor major drug enter clinic develop
fail reach market
competit risk drug market develop condit program address lack
differenti clinic data drug and/or approv competit drug may advers impact sale potenti product
regulatori risk like drug develop compani reliant upon fda pace evalu new drug agenc
willing approv new drug
sector risk valuat biotechnolog stock subject investor assess prospect underli compani investor
toler risk confid prospect biotechnolog stock group therefor stock price may fall even
compani meet exce investor expect
